Atsena Therapeutics is a clinical-stage ocular gene therapy company developing treatments for inherited forms of blindness. It develops an adeno-associated virus technology platform tailored to overcome hurdles presented by inherited retinal disease. Atsena's medical programs include gene therapies for leading forms of Leber congenital amaurosis and Usher syndrome.
|HQ||Durham, NC, US||Map|
|Employees (est.) (Sept 2021)||19|
Atsena Therapeutics total Funding
Atsena Therapeutics latest funding size
Time since last funding
|10 months ago|
Atsena Therapeutics investors
|Osage University Partners, Abingworth, Hatteras Venture Partners, Lightstone Ventures, Sofinnova Investments, PBM Capital, University of Florida, Manning Family Foundation, RD Fund|
When was Atsena Therapeutics founded?
Atsena Therapeutics was founded in 2019.
How many employees does Atsena Therapeutics have?
Atsena Therapeutics has 19 employees.
Who are Atsena Therapeutics competitors?
Competitors of Atsena Therapeutics include Midwest Medical, AnchorDx and Lupagen.
Where are Atsena Therapeutics offices?
Atsena Therapeutics has offices in Durham and Boston.
How many offices does Atsena Therapeutics have?
Atsena Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies